PDCD1 and gastric cancer: Two single‐arm, phase II studies (NCT02954536, NCT02901301) have demonstrated the clinical efficacy and safety for the combination of anti‐PD1 antibody, trastuzumab, and chemotherapy in metastatic HER2‐positive GC patients.10, 11, 12